Author:
Levitan Bennett,Phillips Lawrence D.,Walker Stuart
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference33 articles.
1. Walker S, Liberti L, McAuslane N, Levitan BS. Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters. Clin Pharmacol Ther. 2011;89:179–182.
2. European Medicines Agency. Benefit-risk methodology project: EMA/213482/2010. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/04/WC500089603.pdf. Accessed April 25, 2014.
3. Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther. 2011;89:312–315.
4. Levitan BS, Andrews EB, Gilsenan A, et al. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011;89:217–224.
5. FDA Center for Devices and Radiological Health. Guidance for industry and Food and Drug Administration staff: factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM296379.pdf. Published March 28, 2012. Accessed April 25, 2014.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献